Detalhe da pesquisa
1.
Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma.
Br J Clin Pharmacol
; 89(5): 1640-1655, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36484341
2.
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors.
Invest New Drugs
; 33(3): 691-9, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25895965
3.
FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia.
J Pharmacokinet Pharmacodyn
; 41(6): 675-91, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25326874
4.
Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non-Small Cell Lung Cancer.
Clin Pharmacol Ther
; 115(3): 468-477, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37776107
5.
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
Cancer
; 118(24): 6152-61, 2012 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22692704
6.
Investigation of the mechanism of clearance of AMG 386, a selective angiopoietin-1/2 neutralizing peptibody, in splenectomized, nephrectomized, and FcRn knockout rodent models.
Pharm Res
; 29(4): 1057-65, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22189693
7.
Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab.
J Pharmacokinet Pharmacodyn
; 39(5): 577-90, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22932917
8.
Population-based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma.
Clin Transl Sci
; 15(12): 3000-3011, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36204820
9.
Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis.
J Clin Pharmacol
; 62(5): 656-669, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34708423
10.
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Target Oncol
; 17(4): 433-439, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35749004
11.
Motesanib diphosphate in progressive differentiated thyroid cancer.
N Engl J Med
; 359(1): 31-42, 2008 Jul 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-18596272
12.
Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
BMC Cancer
; 11: 313, 2011 Jul 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-21791058
13.
Investigation of the pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism.
Pharm Res
; 28(8): 1931-8, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21476045
14.
Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients.
J Clin Pharmacol
; 61(5): 614-627, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33145788
15.
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
Adv Ther
; 37(4): 1464-1478, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32078124
16.
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
Adv Ther
; 35(11): 1859-1872, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30374808
17.
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Target Oncol
; 17(5): 609, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35913648
18.
Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects.
J Clin Pharmacol
; 45(4): 468-76, 2005 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15778428
19.
Pharmacokinetic drug-drug interaction assessment of peptibody trebananib in combination with chemotherapies.
Cancer Chemother Pharmacol
; 76(2): 243-50, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26032239
20.
Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.
Breast
; 24(3): 182-90, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25747197